Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioMS misses Phase II primary endpoint

BioMS (TSE:MS) said its MBP8298 peptide did not meet the primary endpoint of stabilizing progression of multiple sclerosis (MS) as measured

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE